pbyi20211231_10k.htm
Neratinib | C30H29ClN6O3 | CID 9915743 - PubChem
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Mechanism of action | NERLYNX® (neratinib) tablets
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Bio FDA Advisory Panel Live Blog - TheStreet
Nerlynx (neratinib) Cancer Medication - Cancer Health
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
Mission Accomplished – 365 Days on Nerlynx – Ela K. Browder
FDA panel backs Puma's neratinib, clearing path to approval | Fierce Biotech
Puma Biotechnology expands deal with Pierre Fabre to include additiona
Puma Biotechnology
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | BioSpace
Nerlynx: Package Insert - Drugs.com
Puma Biotech anti-HER2 breast cancer drug approved in China - BioTuesdays
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Neratinib | 99.94%(HPLC) | In Stock | HER2 inhibitor
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer - ScienceDirect
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers | Nature Communications
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting | Business Wire
Buy Nerlynx (neratinib) Online • Price & Costs | Everyone.org
Puma Biotechnology Surging
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Neratinib for breast cancer – the key is managing gastrointestinal toxicity | Cancer Biology
Neratinib - Wikipedia
Neratinib for breast cancer – the key is managing gastrointestinal toxicity | Cancer Biology
